rheumatoid arthritis

AbbVie's Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst
AbbVie's Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst
Fierce Pharma
AbbVie
Rinvoq
Xeljanz
FDA
rheumatoid arthritis
Flag link:
AbbVie's approval delay raises further concerns about JAK drugs
AbbVie's approval delay raises further concerns about JAK drugs
BioPharma Dive
AbbVie
FDA
Rinvoq
rheumatoid arthritis
Flag link:
FDA holds back from action over Xeljanz safety study FDA holds back from action over Xeljanz safety study
FDA holds back from action over Xeljanz safety study FDA holds back from action over Xeljanz safety study
Pharmaforum
Pfizer
FDA
Xeljanz
rheumatoid arthritis
Flag link:
Pfizer bags rheumatoid arthritis rights to new immunotherapy class through deal with Imcyse
Pfizer bags rheumatoid arthritis rights to new immunotherapy class through deal with Imcyse
Fierce Biotech
Pfizer
Imcyse
rheumatoid arthritis
drug development
Flag link:
Aclaris MK2 bears fruit
Aclaris MK2 bears fruit
EP Vantage
Aclaris
rheumatoid arthritis
clinical trials
ATI-450
Flag link:
Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild
Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild
Bizjournals
Gilead Sciences
Galapagos
clinical trials
filgotinib
rheumatoid arthritis
inflammatory bowel disease
Flag link:
Gilead stops 3 filgotinib trials pending FDA feedback on faltering JAK1 inhibitor
Gilead stops 3 filgotinib trials pending FDA feedback on faltering JAK1 inhibitor
Fierce Biotech
Gilead Sciences
filgotinib
FDA
rheumatoid arthritis
Flag link:
FDA rejects Gilead's would-be blockbuster filgotinib over toxicity concerns
FDA rejects Gilead's would-be blockbuster filgotinib over toxicity concerns
Fierce Biotech
Gilead Sciences
filgotinib
rheumatoid arthritis
FDA
clinical trials
Flag link:
5 FDA approval decisions to watch in the 3rd quarter
5 FDA approval decisions to watch in the 3rd quarter
BioPharma Dive
FDA
Gilead Sciences
filgotinib
rheumatoid arthritis
GSK
belantamab mafodotin
Multiple Myeloma
NS Pharma
viltolarsen
Duchenne Muscular Dystrophy
Flag link:
Amgen's Enbrel Patents to Be Upheld Through 2029
Amgen's Enbrel Patents to Be Upheld Through 2029
Motley Fool
psoriasis
rheumatoid arthritis
Enbrel
Novartis
biosimilars
patents
Flag link:
Gilead shows durability of filgotinib ahead of face-off with AbbVie
Gilead shows durability of filgotinib ahead of face-off with AbbVie
Fierce Biotech
Gilead Sciences
Galapagos
clinical trials
filgotinib
rheumatoid arthritis
Flag link:
Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug
Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug
BioPharma Dive
Galapagos
Gilead Sciences
filgotinib
rheumatoid arthritis
FDA
COVID-19
Flag link:
Gilead gets ball rolling on JAKs game in Japan
Gilead gets ball rolling on JAKs game in Japan
Endpoints
Gilead Sciences
Japan
filgotinib
Eisai
rheumatoid arthritis
Flag link:
As promised, Gilead and Galapagos file filgotinib to FDA and get a speedy review
As promised, Gilead and Galapagos file filgotinib to FDA and get a speedy review
Fierce Biotech
Gilead Sciences
FDA
filgotinib
Galapagos
rheumatoid arthritis
Flag link:
Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster
Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster
Fierce Pharma
Amgen
Enbrel
Abarca
PBMs
rheumatoid arthritis
Flag link:
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
Pharmaforum
ICER
AbbVie
Rinvoq
rheumatoid arthritis
biosimilars
Flag link:
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
Fierce Pharma
ICER
AbbVie
Rinvoq
rheumatoid arthritis
JAK inhibitors
Flag link:
Gilead, Galapagos share 52-week update on filgotinib
Gilead, Galapagos share 52-week update on filgotinib
Fierce Biotech
Gilead Sciences
Galapagos
filgotinib
clinical trials
rheumatoid arthritis
Flag link:
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
Fierce Pharma
ICER
JAK inhibitors
rheumatoid arthritis
AbbVie
Rinvoq
Pfizer
Xeljanz
Incyte
olumiant
Flag link:
Rheumatoid Arthritis Drug May Help Repair Heart After Heart Attacks
Rheumatoid Arthritis Drug May Help Repair Heart After Heart Attacks
BioSpace
VentriGel
Ventrix
rheumatoid arthritis
heart attacks
Flag link:

Pages